SCHEMBL6002245

SCHEMBL6002245

O=C(OCc1ccccc1)c1ccc2cc(C(=O)OCc3ccccc3)ccc2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.70
TDP1 Q9NUW8 4/20 0.70
SLC6A2 P23975 1/20 0.70
SLC6A3 Q01959 1/20 0.70
LMNA P02545 3/20 0.69
ALDH1A1 P00352 7/20 0.63
RAB9A P51151 5/20 0.63
MAPT P10636 4/20 0.63
NPC1 O15118 3/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
HPGD P15428 1/20 0.59
KDM4E B2RXH2 2/20 0.57
HTT P42858 1/20 0.57
MEN1 O00255 1/20 0.55
GAA P10253 1/20 0.54
L3MBTL1 Q9Y468 2/20 0.51
MAPK1 P28482 1/20 0.50
NR4A1 P22736 1/20 0.50
NR4A2 P43354 1/20 0.50
NR4A3 Q92570 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2706461 0.97 KMT2A (0.66) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL6001946 0.95 KMT2A (0.64) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL9616998 0.94 LMNA (0.71) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL6001726 0.91 KMT2A (0.58) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL3235219 0.91 ALOX5 (0.61) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL6000300 0.91 KMT2A (0.58) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL11862997 0.90 KMT2A (0.66) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL25462523 0.89 KDM4E (0.58) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL21511088 0.89 LMNA (0.69) KMT2ATDP1SLC6A2SLC6A3LMNA
SCHEMBL19721589 0.88 TDP1 (0.55) KMT2ATDP1SLC6A2SLC6A3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1212296-B9 PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS SUGEN INC (US) 2006-05-10 EP disclosed
EP-1212296-B1 PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS SUGEN INC (US) 2005-11-09 EP disclosed
EP-1004621-B1 GAMMA-RAY STABILIZER AND THERMOPLASTIC POLYMER COMPOSITION CONTAINING THE SAME TEIJIN CHEMICALS LTD (JP) 2004-09-15 EP disclosed
EP-0964014-B1 Aromatic liquid crystalline polyester resin and resin composition thereof SUMITOMO CHEMICAL CO (JP) 2004-08-18 EP disclosed
US-20040138255-A1 Phosphate mimics and methods of treatment using phosphatease inhibitors SUGEN, INC. 2004-07-15 US disclosed
US-6596772-B1 Relates to trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and the physiologically acceptable salts and the prodrugs thereof. These compounds are expected to modulate the activity of protein tyrosine enzymes which are SUGEN, INC. 2003-07-22 US disclosed
US-6485657-B1 Gamma-ray stabilizer and thermoplastic polymer compound including the said stabilizer TEIJIN, LIMITED (JP) 2002-11-26 US disclosed
EP-1212296-A1 PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS Sugen, Inc. (US) 2002-06-12 EP disclosed
US-6376076-B1 LOW TEMPERATURE; MELT PROCESSABILITY SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-04-23 US disclosed
US-6296930-B1 HEAT-RESISTANCE FOR USE AS WRAPPING MATERIAL AND LOW TEMPERATURE PROCESSABILITY, GAS BARRIER PROPERTY SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-10-02 US disclosed
WO-2001016097-A1 PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS SUGEN, INC. (US) 2001-03-08 WO disclosed
EP-1004621-A1 GAMMA-RAY STABILIZER AND THERMOPLASTIC POLYMER COMPOSITION CONTAINING THE SAME TEIJIN LIMITED (JP) 2000-05-31 EP disclosed
EP-0964014-A2 Aromatic liquid crystalline polyester resin and resin composition thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1999-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138255-A1 Phosphate mimics and methods of treatment using phosphatease inhibitors PPP4C, PTPRO, PTPRS KMT2A 2785/4885TDP1 375/4885SLC6A2 2750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.